| Name | Title | Contact Details |
|---|
Clinical Research of West Florida is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Community Health Resources` (CHR) mission is to help adults, children and families find Real Hope for the challenges of Real Life through an array of community based mental health, substance use, child welfare, supported housing, foster care, prevention and wellness services and integrated care. Our name embodies our commitment to community based care, utilizing all available resources to achieve change, and instill hope for a healthy, happy and productive future. CHR is proud to provide services that achieve Real Quality with Real Results. CHR’s history dates back to the 1960s, and since its creation, has become a trusted community resource and well-respected service provider. We employ over 700 experienced staff members who provided services to more than 18,000 individuals in the past year. We offer effective, accesible and affordable behavioral healthcare through 80 programs and 32 locations. As we anticipate changing needs, we will offer new programs, recruit exceptional staff, collaborate with other providers, and explore new funding sources. The driving force of our growth continues to be meeting the needs of those we serve.
AOR Canada Advanced Orthomolecular Research Inc is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We build applications that use speech and fine motor to detect subtle changes in brain health. We are rooted in neuroscience with an award winning, first to market technology platform that turns the devices we use every day into objective brain health monitors.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.